Starpharma Advances Strategic Goals with DEP SN38 and Global Collaborations in Q2 FY25.

Starpharma (ASX: SPL) has made significant strides in its Q2 FY25 activities, advancing its strategic priorities and enhancing its dendrimer technology platform. Key highlights include positive feedback from the FDA for the clinical pathway of DEP SN38 in treating Platinum-Resistant Ovarian Cancer, with potential for Fast Track designation and accelerated approval. The DEP radiopharmaceuticals program also progressed, with active discussions with global collaborators. Additionally, VivaGel BV is set to launch in Saudi Arabia and the UAE in Q4 FY25, while online sales of Viraleze improved significantly after digital marketing enhancements. 

The company concluded 2024 with a strong cash balance of AU$20.3 million and multiple commercialization opportunities for 2025. Strategic engagements with partners like Petalion and regulatory progress for DEP SN38 and cabazitaxel further strengthen its pipeline. CEO Cheryl Maley highlighted the robust potential of Starpharma’s dendrimer technology and its commitment to addressing unmet medical needs through innovation.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com